{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-001252","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.113470+00:00","generated_at":"2026-06-27T20:40:11.413462+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bicycle reports 1 confirmed complete response in BT8009 Phase I; management restructured","bullets":["BT8009 Phase I: 4/11 partial responses; one confirmed complete response (100% tumor reduction) at 5.0 mg/m2.","Dose escalation continues at 7.5 mg/m2; interim Phase I results to be presented at a 2022 medical meeting.","BT5528 Phase I/II on track to initiate expansion cohorts in 2022 with RP2D of 6.5 mg/m2 every-other-week.","BT7480 Phase I dose escalation ongoing; four SITC posters on Bicycle TICAs including NK-cell-engaging molecule.","Michael Skynner becomes CTO (new role); Alistair Milnes promoted to COO, both effective Jan 3, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-001252","json":"https://secwatch.observer/filing/0001104659-22-001252.json","markdown":"https://secwatch.observer/filing/0001104659-22-001252.md","text":"https://secwatch.observer/filing/0001104659-22-001252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/0001104659-22-001252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/tm221573d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:40:11.413462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"001a71be0e","claim":"Alistair Milnes was appointed as Chief Operating Officer at BICYCLE THERAPEUTICS PLC.","evidence_excerpt":"On January 5, 2022, Bicycle Therapeutics plc (the “Company”) announced the appointment of Alistair Milnes, age 48, as the Company’s Chief Operating Officer, effective as of January 3, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/0001104659-22-001252-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"513f652a5b","claim":"Michael Skynner changed role as Chief Technology Officer at BICYCLE THERAPEUTICS PLC.","evidence_excerpt":"following the transition of Michael Skynner, Ph.D. to the newly-created role of Chief Technology Officer of the Company as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/0001104659-22-001252-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned to"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}